Skip to main content
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
letter
. 2022 Mar 28;50(6):1615. doi: 10.1007/s15010-022-01812-z

Hemophagocytic lymphohistiocytosis and SARS-CoV-2 vaccination

Rujittika Mungmunpuntipantip 1,, Viroj Wiwanitkit 2
PMCID: PMC8960700  PMID: 35349078

Dear Editor, we would like to share ideas on the publication “Hemophagocytic lymphohistiocytosis (HLH) after SARS-CoV-2 vaccination [1].” Hieber et al. mentioned that “COVID-19 vaccines may occasionally trigger HLH, and Anakinra may be an efficacious treatment option for this condition [1].” The COVID-19 vaccines can cause unwanted adverse effect and HLH might be a clinical adverse effect. In the present case, the patient had HLH. However, there are no data on pre-vaccination immune/health status of this case. The HLH might or might not be an adverse effect of the COVID-19 vaccine. The possibility of a concurrent medical problem should be discussed. For example, dengue is a possible concurrent medical problem [2] and HLH might be the complication of dengue infection [3].

Author contributions

RM 50%—1a Substantial contributions to study conception and design. 1b. Substantial contributions to acquisition of data. 1c. Substantial contributions to analysis and interpretation of data. 2. Drafting the article or revising it critically for important intellectual content. 3. Final approval of the version of the article to be published. VW 50%—1a Substantial contributions to study conception and design. 1b. Substantial contributions to acquisition of data. 1c. Substantial contributions to analysis and interpretation of data. 2. Drafting the article or revising it critically for important intellectual content. 3. Final approval of the version of the article to be published.

Funding

None.

Availability of data and materials

Not applicable.

Declarations

Conflict of interest

The authors are from poor developing country and cannot pay for any charge and ask for full waiving for this correspondence letter. Rujittika Mungmunpuntipantip and other co-authors have no conflict of interest.

Ethical approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

References

  • 1.Hieber ML, Sprute R, Eichenauer DA, Hallek M, Jachimowicz RD. Hemophagocytic lymphohistiocytosis after SARS-CoV-2 vaccination. Infection. 2022 doi: 10.1007/s15010-022-01786-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Kebayoon A, Wiwanitkit V. Dengue after COVID-19 vaccination: possible and might be missed. Clin Appl Thromb Hemost. 2021;27:10760296211047229. doi: 10.1177/10760296211047229. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Munshi A, Alsuraihi A, Balubaid M, Althobaiti M, Althaqafi A. Dengue-induced hemophagocytic lymphohistiocytosis: a case report and literature review. Cureus. 2021;13:e20172. doi: 10.7759/cureus.20172. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

Not applicable.


Articles from Infection are provided here courtesy of Nature Publishing Group

RESOURCES